P. Brian Mckeon's Insider Trades & SAST Disclosures
P. Brian Mckeon's most recent trade in Idexx Laboratories, Inc. was a trade of 569 Common Stock done at an average price of $444.5 . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern P. Brian Mckeon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 14 Feb 2025 | 569 | 31,549 (0%) | 0% | 444.5 | 252,938 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 308 | 615 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 308 | 31,819 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 303 | 303 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 303 | 31,511 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 299 | 894 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 299 | 32,118 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 252 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 252 | 31,208 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 192 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 192 | 31,048 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 455.08 per share. | 05 Aug 2024 | 117 | 30,931 (0%) | 0% | 455.1 | 53,244 | Common Stock |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 29,245 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 27,780 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Idexx Laboratories, Inc. | P. Mckeon Brian | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 483 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 15 Feb 2024 | 483 | 30,834 (0%) | 0% | 206.9 | 99,952 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 5,355 | 5,355 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Mckeon Brian P. | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 1,193 | 1,193 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | P. Mckeon Brian | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 1,097 | 30,351 (0%) | 0% | 560.6 | 614,934 | Common Stock |
| Idexx Laboratories, Inc. | Mckeon P. Brian | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 435 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | P. Brian Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 435 | 30,152 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 432 | 30,584 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 432 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | P. Brian Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 308 | 923 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 308 | 31,448 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | P. Mckeon Brian | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 303 | 31,140 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 303 | 606 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 253 | 252 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | P. Brian Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 253 | 30,837 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Alkermes plc | P. Brian Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Mckeon Brian P. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 24,229 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.32 per share. | 10 Feb 2024 | 1,088 | 23,141 (0%) | 0% | 27.3 | 29,724 | Ordinary Shares |
| Alkermes plc | P. Brian Mckeon | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 523 | 26,692 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Mckeon P. Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian Mckeon P. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | P. Brian Mckeon | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 90 | 4,639 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 88 | 4,533 | - | - | Restricted Stock Unit Award | |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 23,326 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | P. Brian Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 07 Feb 2024 | 23,326 | 53,043 (0%) | 0% | 141.6 | 3,302,962 | Common Stock |
| Idexx Laboratories, Inc. | P. Brian Mckeon | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 571.84 per share. | 07 Feb 2024 | 7,128 | 30,398 (0%) | 0% | 571.8 | 4,076,062 | Common Stock |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 570.97 per share. | 07 Feb 2024 | 5,675 | 37,526 (0%) | 0% | 571.0 | 3,240,253 | Common Stock |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 569.91 per share. | 07 Feb 2024 | 3,912 | 43,201 (0%) | 0% | 569.9 | 2,229,500 | Common Stock |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 564.98 per share. | 07 Feb 2024 | 1,581 | 50,847 (0%) | 0% | 565.0 | 893,227 | Common Stock |
| Idexx Laboratories, Inc. | Mckeon P. Brian | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 567.35 per share. | 07 Feb 2024 | 1,564 | 48,582 (0%) | 0% | 567.3 | 887,333 | Common Stock |
| Idexx Laboratories, Inc. | Mckeon Brian P. | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 568.84 per share. | 07 Feb 2024 | 1,469 | 47,113 (0%) | 0% | 568.8 | 835,633 | Common Stock |
| Idexx Laboratories, Inc. | P. Brian Mckeon | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 566.53 per share. | 07 Feb 2024 | 701 | 50,146 (0%) | 0% | 566.5 | 397,140 | Common Stock |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 572.80 per share. | 07 Feb 2024 | 681 | 29,717 (0%) | 0% | 572.8 | 390,080 | Common Stock |
| Idexx Laboratories, Inc. | Brian Mckeon P. | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 563.82 per share. | 07 Feb 2024 | 615 | 52,428 (0%) | 0% | 563.8 | 346,747 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 192 | 3,704 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 192 | 29,809 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 504.08 per share. | 05 Aug 2023 | 117 | 29,692 (0%) | 0% | 504.1 | 58,977 | Common Stock |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,126 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 19,696 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 12,732 | 12,732 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 5,985 | 5,985 | - | - | Restricted Stock Unit Award | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 05 May 2023 | 560 | 29,605 (0%) | 0% | 178.3 | 99,826 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2023 | 560 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 503.65 per share. | 14 Feb 2023 | 1,208 | 29,030 (0%) | 0% | 503.6 | 608,409 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 504 | 28,814 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 504 | 5,320 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 435 | 29,249 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 435 | 4,885 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 433 | 29,682 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 433 | 4,452 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 303 | 3,896 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 303 | 30,238 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 253 | 29,935 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 253 | 4,199 | - | - | Restricted Stock Unit | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 4,445 | 15,169 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 4,445 | 4,445 | - | - | Restricted Stock Unit Award | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 8,811 | 8,811 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 1,231 | 5,824 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 201 | 201 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 192 | 4,593 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 192 | 28,365 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 407.78 per share. | 05 Aug 2022 | 90 | 28,275 (0%) | 0% | 407.8 | 36,700 | Common Stock |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 11,554 | 11,554 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 5,957 | 5,957 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 11,519 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.19 per share. | 14 Jun 2022 | 795 | 10,724 (0%) | 0% | 27.2 | 21,616 | Ordinary Shares |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 16 Feb 2022 | 706 | 28,153 (0%) | 0% | 141.6 | 99,970 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 706 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 10,502 | 10,502 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,212 | 6,870 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 505.53 per share. | 14 Feb 2022 | 964 | 27,447 (0%) | 0% | 505.5 | 487,331 | Common Stock |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 505 | 5,906 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 505 | 27,290 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 459 | 6,411 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 459 | 26,785 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 435 | 5,471 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 435 | 27,725 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 433 | 5,038 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Brian P. Mckeon | Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 433 | 28,158 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges